Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

安必平首次公开发行股票募集资金总额为7.13亿元，扣除发行费用后，募集资金净额为6.40亿元。 安必平最终募集资金净额较原计划多2.66亿元。安必平于2020年8月14日发布的招股说明书显示，该公 司计划募集资金3.74亿元，分别用于研发生产基地建设项目、营销服务网络升级建设项目。 安必平首次公开发行股票的发行费用为7332.49万元，其中，保荐及承销费用5719.62万元。 (责任编辑：何潇) 安必平于2020年8月20日在上交所科创板上市，发行数量为2334万股，发行价格30.56元/股，保荐 机构为民生证券（现为国联民生证券股份有限公司），保荐代表人为何尔璇、杨芳。 安必平于上市首日盘中创下股价最高点74.00元，为该股上市以来最高价。 中国经济网北京12月23日讯 安必平(688393.SH)今日收报23.60元，跌幅3.95%。目前该股处于破发 状态。 ...

Group 1 - The medical device sector increased by 0.56% on December 19, with Kangzhong Medical leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] - Notable gainers in the medical device sector included Kangzhong Medical, which rose by 7.36% to a closing price of 44.90, and Rendu Biotech, which increased by 6.78% to 50.40 [1] Group 2 - The medical device sector experienced a net inflow of 3.65 million yuan from institutional investors, while retail investors saw a net inflow of 15 million yuan [2] - Major stocks with significant net inflows included Rejing Bio with 49.71 million yuan and Yuyue Medical with 43.84 million yuan [3] - Conversely, retail investors showed net outflows in several stocks, including Yuyue Medical and Mairui Medical, indicating a mixed sentiment in the market [3]

早盘AI医疗概念震荡回升，华人健康涨近15%，此前鹭燕医药2连板，美年健康、安必平、成都先导、 塞力医疗跟涨。 ...

（文章来源：证券日报） 证券日报网讯 12月11日，安必平在互动平台回答投资者提问时表示，股票价格受宏观经济环境、市场 行情、板块热点等多种因素影响。公司始终坚持聚焦病理行业，多措并举抓好生产经营，保证信息披露 及时、准确，不断加强市值管理。 ...

Group 1 - The company, Nanjing Qianjing Venture Capital Partnership, held 1,677,265 shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.79% of the total share capital before the reduction plan [1] - The reduction plan involved Nanjing Qianjing intending to reduce its holdings by up to 1,677,265 shares through centralized bidding and block trading, which represents 1.79% of the company's total share capital [1] - As of December 3, 2025, Nanjing Qianjing had reduced its holdings by 174,922 shares, which is 0.19% of the total share capital, and the reduction plan period has expired [1][3] Group 2 - The reduction subject has no concerted actions with other parties [2] - The actual reduction complied with relevant laws and regulations, and the actual reduction was consistent with the previously disclosed reduction plan [5] - The reduction plan was fully implemented, and there were no violations of the reduction plan or other commitments [5]

（编辑 袁冠琳） 证券日报网讯 12月3日晚间，安必平发布公告称，南京乾靖创业投资合伙企业（有限合伙）于2025年9 月4日至12月3日以集中竞价方式累计减持公司股票174，922股，减持比例占公司总股本0.19%，减持计 划时间区间已届满。 ...

证券代码：688393 证券简称：安必平 公告编号：2025-052 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东的基本情况 广州安必平医药科技股份有限公司 本次减持计划实施前，南京乾靖创业投资合伙企业（有限合伙）（以下简称 "南京乾靖"）持有广州安必平医药科技股份有限公司（以下简称"公司"） 1,677,265 股股份，占公司总股本的比例为 1.79%，该等股份为南京乾靖于公司 首次公开发行并上市前取得的股份，且已于 2021 年 8 月 20 日解除限售后上市流 通。 股东减持股份计划时间届满暨减持股份结果公告 减持计划的实施结果情况 2025 年 8 月 14 日，公司披露了《广州安必平医药科技股份有限公司股东减 持股份计划公告》（公告编号：2025-033），南京乾靖拟通过集中竞价方式及大 宗交易方式减持所持有的公司股份不超过 1,677,265 股(含本数)，不超过公司目 前总股本的 1.79%。 2025 年 12 月 3 日，公司收到股东南京乾靖发来的《关于股份减持的告知函 ...

格隆汇12月3日丨安必平(688393.SH)公布，2025年12月3日，公司收到股东南京乾靖发来的《关于股份 减持的告知函》,减持计划期间南京乾靖以集中竞价的方式累计减持公司股票17.49万股，减持比例占公 司总股本0.19%。本次减持计划时间区间已届满。 ...

Group 1 - Recent collaboration between Anbiping (688393.SH) and CSPC Pharmaceutical Group (1093.HK) focuses on the development of C-MET companion diagnostics [1] - Anbiping will be responsible for the development of immunohistochemistry companion diagnostic products and the commercialization of IVD/CDx kits, enhancing clinical applications for cancer patients [2] - CSPC Pharmaceutical Group, established in 1997, has maintained double-digit growth in key operational metrics and is recognized for its innovative development in the pharmaceutical industry [3] Group 2 - CSPC has two national key laboratories and over 60 products with annual sales exceeding 100 million, covering APIs, chemical drugs, biological drugs, and functional foods [3] - Anbiping, founded in 2005, is the first listed company in China focusing on pathology diagnostics, with over 200 self-developed immunohistochemistry antibodies and advanced digital + AI-assisted diagnostic products [4] - Anbiping serves over 3,000 medical institutions nationwide through its comprehensive business model that includes tumor screening, pathology diagnosis, smart pathology, and pathology services [4]